You are here

Valpam 5 (diazepam) 5 mg tablets

Product defect alert - potential for blister strip to contain lower strength tablets

5 June 2018

Consumers and health professionals are advised that Arrow Pharma, in consultation with the TGA, has issued a product defect alert for one batch of Valpam 5 due to the possibility of the blister strip including white Valpam 2 mg tablets, instead of yellow Valpam 5 mg tablets.

A single Valpam 2 mg tablet was found in a blister pack of Valpam 5 mg tablets.
A single Valpam 2 mg tablet was found in a blister
pack of Valpam 5 mg tablets
.

The affected batch (numbered CP218) contains Valpam 5 mg tablet blister packs (50 tablets) with an expiry date of January 2021.

The alert follows one instance where a single Valpam 2 mg tablet was found in a blister pack of Valpam 5 mg tablets from Batch CP218. No other batches are known to be affected.

Arrow advises consumers and health professionals to visually inspect blisters from batch CP218 before dispensing or use, in order to ensure that all of the tablets in a given blister are coloured light yellow. The correct tablets should be marked with ‘DZ 5’ on one side, however this marking will only be visible on tablets that are loaded into the packaging with the numbered side facing the clear plastic blister.

If a blister is found to contain a white or off-white tablet alongside the other yellow tablets, these blisters are affected and should not be used or supplied.

If no anomalies are found the product may continue to be supplied and used as normal and no further action is necessary.

As a precautionary measure, consumers and health professionals may choose to visually inspect all Valpam 5 packs from any batch number currently on hand, however, only one batch is currently known to be involved.

Consumers are advised to return any affected blisters unopened to the place of purchase for refund or replacement.

For further information, contact Arrow Pharma on 1800 941 148.

Reporting problems

Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to the TGA's monitoring of these products.

The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.